⚠ FOR RESEARCH USE ONLY
Lumo-1 SMG

CHEMICAL PROPERTIES

CAS NUMBER910463-68-2
MOLECULAR WEIGHT4113.58 g/mol
MOLECULAR FORMULAC₁₈₇H₂₉₁N₄₅O₅₉

PHYSICAL PROPERTIES

APPEARANCEWhite lyophilized powder in sealed borosilicate glass vial.
SEQUENCEHis-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg
Metabolic Research

Lumo-1 SMG

Semaglutide is a GLP-1 receptor agonist analogue of human glucagon-like peptide-1. Extensively studied in clinical trials for metabolic regulation, appetite suppression, and cardiovascular risk reduction.

1
Free shipping on orders over $150
2-day delivery
LOT NUMBERLMO-DS-0626-SMG-001
REPORT NO.RPT-20020
HPLC PURITY98.50%

7× Independently Tested

HPLC PurityIndependent lab
IdentitySequence confirmed
Net ContentExact mg verified
SterilityContamination-free
EndotoxinsLAL tested
Heavy MetalsICP-MS screened
Batch ConsistencyLot-to-lot stability
7×
TESTED
⚠

RESEARCH USE ONLY

This compound is sold strictly for in vitro research and laboratory use. Not for human or animal consumption. Not a drug, food, or supplement. By purchasing you confirm you are a qualified researcher and will use this compound in compliance with all applicable laws. Must be 21 or older.

RESEARCH

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6)
Marso SP, Bain SC, Consoli A, et al. · New England Journal of Medicine · 2016
Pivotal cardiovascular outcomes trial demonstrating once-weekly semaglutide significantly reduced major adverse cardiovascular events by 26% versus placebo in patients with type 2 diabetes at high cardiovascular risk.
PMID 27633186
Comparative Efficacy, Safety, and Cardiovascular Outcomes With Once-Weekly Subcutaneous Semaglutide: Insights From the SUSTAIN 1-7 Trials
Aroda VR, Ahmann A, Cariou B, et al. · Diabetes & Metabolism · 2019
Comprehensive review of the SUSTAIN 1-7 trial programme showing semaglutide consistently demonstrated superior glycaemic control and weight loss versus all comparators, with significant cardiovascular event reduction in high-risk patients.
PMID 30615985
Cardiometabolic Risk Factors Efficacy of Semaglutide in the STEP Program
Multiple authors · Diabetes, Obesity and Metabolism · 2023
Reports semaglutide 2.4mg produced significant improvements in body weight, waist circumference, blood pressure, and lipid profile across the STEP 1-5 obesity trial programme compared to placebo.
PMID 36691308

LAB RESULTS

LOT LMO-DS-0626-SMG-001 · CURRENT

Certificate of Analysis

PURITY
98.50%
CAS
910463-68-2
MW
4113.58 g/mol
APPEARANCE
White lyophilized powder in sealed borosilicate glass vial.
VERIFIED

Third-Party Report

TESTING LABIndependent Analytics LLC
TEST DATEJanuary 2025
METHODS USED
HPLCMSAAA
RESEARCH APPLICATIONS

What the literature covers.

  • ●GLP-1 receptor agonist studied in large-scale cardiovascular outcome trials
  • ●Investigated for sustained weight reduction in obesity research protocols
  • ●Evaluated for glucose-dependent insulin secretion modulation
  • ●Long-acting fatty acid conjugation studied for extended half-life pharmacokinetics

All compounds sold by Lumo are intended strictly for in vitro research and laboratory use only. These products are NOT intended for human consumption, medical, veterinary, or household use. By purchasing from Lumo, you acknowledge that you are a qualified researcher or institution and will use these products solely for research purposes in compliance with all applicable laws and regulations.

L-003

Stay current.

New lot releases, research updates, and product announcements.

Unsubscribe anytime. Research use communications only.

Research Use Only · Not for Human Consumption · For Laboratory Research Purposes Only

Your Cart

● All items for research use only. Not for human consumption.
●

Your cart is empty

Add compounds to get started